NO20022232L - Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII - Google Patents

Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII

Info

Publication number
NO20022232L
NO20022232L NO20022232A NO20022232A NO20022232L NO 20022232 L NO20022232 L NO 20022232L NO 20022232 A NO20022232 A NO 20022232A NO 20022232 A NO20022232 A NO 20022232A NO 20022232 L NO20022232 L NO 20022232L
Authority
NO
Norway
Prior art keywords
inhibitors
imidazole compounds
phosphodiesterase vii
cycloalkyl
phosphodiesterase
Prior art date
Application number
NO20022232A
Other languages
English (en)
Other versions
NO20022232D0 (no
Inventor
Hans Michael Eggenweiler
Rochus Jonas
Michael Wolf
Michael Gassen
Thomas Welge
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20022232L publication Critical patent/NO20022232L/no
Publication of NO20022232D0 publication Critical patent/NO20022232D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Imidazolforbindelser med formel (I) hvor R1 og R2 uavhengig av hverandre betyr H, A1, OA1, SA1 eller Hal; A1 betyr H, A, alkenyl, sykloalkyl eller alkylensykloalkyl; A betyr alkyl med 1- 10 C-atomer; Hal betyr F, Cl, Br eller I; og X betyr O, S, SO eller SO2; samt deres fysiologisk akseptable salter og/eller solvater, som fosfodiesterase Vll-inhibitorer, og deres anvendelse til fremstilling av et legemiddel.
NO20022232A 1999-11-13 2002-05-10 Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII NO20022232D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19954707A DE19954707A1 (de) 1999-11-13 1999-11-13 Imidazolverbindungen als Phosphodiesterase VII-Hemmer
PCT/EP2000/010765 WO2001036425A2 (de) 1999-11-13 2000-10-31 Imidazolverbindungen als phosphodiesterase vii-hemmer

Publications (2)

Publication Number Publication Date
NO20022232L true NO20022232L (no) 2002-05-10
NO20022232D0 NO20022232D0 (no) 2002-05-10

Family

ID=7928973

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022232A NO20022232D0 (no) 1999-11-13 2002-05-10 Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII

Country Status (23)

Country Link
US (1) US6884800B1 (no)
EP (1) EP1228073B1 (no)
JP (1) JP4819272B2 (no)
KR (1) KR20020049051A (no)
CN (1) CN1390222A (no)
AR (1) AR026421A1 (no)
AT (1) ATE245653T1 (no)
AU (1) AU775886B2 (no)
BR (1) BR0015487A (no)
CA (1) CA2391087A1 (no)
CZ (1) CZ20021474A3 (no)
DE (2) DE19954707A1 (no)
DK (1) DK1228073T3 (no)
ES (1) ES2200968T3 (no)
HU (1) HUP0203422A3 (no)
MX (1) MXPA02004728A (no)
NO (1) NO20022232D0 (no)
PL (1) PL355098A1 (no)
PT (1) PT1228073E (no)
RU (1) RU2002113759A (no)
SK (1) SK6012002A3 (no)
WO (1) WO2001036425A2 (no)
ZA (1) ZA200204729B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2533206T3 (es) * 2007-03-27 2015-04-08 Omeros Corporation Inhibidores de PDE7 para uso en el tratamiento de trastornos del movimiento
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
DE102007047738A1 (de) * 2007-10-05 2009-04-09 Merck Patent Gmbh Imidazolderivate
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN107375296A (zh) 2010-11-08 2017-11-24 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
MX2020000295A (es) 2017-07-12 2020-07-22 Dart Neuroscience Llc Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7.
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2919271A (en) * 1957-12-05 1959-12-29 Smith Kline French Lab 3-amino-1, 2-dihydro-3h-pyrido [3, 2, 1-kl]-phenothiazines
DK0480939T3 (da) * 1989-06-09 1995-07-10 Upjohn Co Heterocycliske aminer med virkning på centralnervesystemet
US5318965A (en) * 1990-08-24 1994-06-07 Abbott Laboratories Quinobenzoxazine, antineoplastic agents
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity

Also Published As

Publication number Publication date
JP4819272B2 (ja) 2011-11-24
US6884800B1 (en) 2005-04-26
CA2391087A1 (en) 2001-05-25
HUP0203422A3 (en) 2004-12-28
CZ20021474A3 (cs) 2002-07-17
SK6012002A3 (en) 2002-09-10
DE19954707A1 (de) 2001-05-17
WO2001036425A3 (de) 2002-01-10
BR0015487A (pt) 2002-07-02
RU2002113759A (ru) 2004-01-10
HUP0203422A2 (hu) 2003-02-28
ZA200204729B (en) 2003-11-26
ATE245653T1 (de) 2003-08-15
NO20022232D0 (no) 2002-05-10
AR026421A1 (es) 2003-02-12
DE50003036D1 (de) 2003-08-28
EP1228073A2 (de) 2002-08-07
AU1390701A (en) 2001-05-30
EP1228073B1 (de) 2003-07-23
JP2003514821A (ja) 2003-04-22
PL355098A1 (en) 2004-04-05
DK1228073T3 (da) 2003-11-03
CN1390222A (zh) 2003-01-08
MXPA02004728A (es) 2002-08-30
KR20020049051A (ko) 2002-06-24
AU775886B2 (en) 2004-08-19
ES2200968T3 (es) 2004-03-16
WO2001036425A2 (de) 2001-05-25
PT1228073E (pt) 2003-12-31

Similar Documents

Publication Publication Date Title
NO20022232L (no) Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII
YU51400A (sh) Derivati 2-piridilmetilamina, kao korisni fungicidi
MY119150A (en) Azetidine derivatives, their preparation and medicaments containing them
TW333527B (en) Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
NO883487L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
NO308248B1 (no) Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat
DK0759919T3 (da) Azolidindioner som antihyperglykæmiske midler
DK170188D0 (da) Carbinolderivater
MX9701685A (es) Nuevos derivados de bencimidazol que tienen la actividad de inhibicion de la fosfodiestearasa cgmp.
NZ313185A (en) 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
PT918776E (pt) Sintese total de acilfulvenos antitumorais
NO20000722L (no) 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater
YU86601A (sh) Derivati purina, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
DE69725585D1 (de) Phenylalkylcarbonsäure-derivate
NO972887L (no) Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel
HUP0302961A2 (hu) (Aminoalkoxibenzoil) benzofuránok vagy benzotiofének, eljárás ilyen vegyületek előállítására és ilyen vegyületeket tartalmazó készítmények
EP0436734A4 (en) New aminopiperazine derivatives
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
NO921159L (no) Tiazolidinon- og oksazolidinonderivater, fremgangsmaate til fremstilling derav, samt anvendelse av derivatene som vasodilatorer
DK0967207T3 (da) Nitron-derivater, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger indeholdende derivaterne
ATE116974T1 (de) 5- piperazinylalkyl-1,5-benzothiazepinone verwendbar als calciumantagonisten.
NO972731D0 (no) Thiazolidinonforbindelser eller middel inneholdende disse for å behandle eller forhindre angina pectoris
ES8506002A1 (es) Procedimiento para la obtencion de 2-(1-indolinil-metil)-imidazolinas
HUP0204168A2 (hu) Butin-diol-származékok, ilyeneket tartalmazó gyógyszerkészítmény és előállítása
TR200003877T2 (tr) İnsan CD23 üretiminin ve TNF salınmasının ihhibitörleri olan hiydroxamic acid türevleri

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application